These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 3100771

  • 1. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
    Kan JP, Steinberg R, Mouget-Goniot C, Worms P, Bizière K.
    J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
    [Abstract] [Full Text] [Related]

  • 2. Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro.
    Kan JP, Steinberg R, Leclercq J, Worms P, Biziere K.
    J Neurochem; 1988 Apr; 50(4):1137-44. PubMed ID: 3346672
    [Abstract] [Full Text] [Related]

  • 3. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
    Gerardy J.
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents.
    Worms P, Kan JP, Wermuth CG, Roncucci R, Bizière K.
    J Pharmacol Exp Ther; 1987 Jan; 240(1):241-50. PubMed ID: 3100770
    [Abstract] [Full Text] [Related]

  • 6. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE.
    J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile.
    Curet O, Damoiseau G, Aubin N, Sontag N, Rovei V, Jarreau FX.
    J Pharmacol Exp Ther; 1996 Apr; 277(1):253-64. PubMed ID: 8613928
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Enhancement of 5-HT-induced anorexia: a test of the reversibility of monoamine oxidase inhibitors.
    Fletcher PJ, Yu PH.
    Psychopharmacology (Berl); 1989 Apr; 98(2):265-8. PubMed ID: 2502797
    [Abstract] [Full Text] [Related]

  • 11. On the reversibility of reversible MAO inhibitors.
    Waldmeier PC.
    Naunyn Schmiedebergs Arch Pharmacol; 1985 May; 329(3):305-10. PubMed ID: 4022138
    [Abstract] [Full Text] [Related]

  • 12. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
    Kumagae Y, Matsui Y, Iwata N.
    Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113
    [Abstract] [Full Text] [Related]

  • 13. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I, Youdim MB, Finberg JP.
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [Abstract] [Full Text] [Related]

  • 14. MD 240928 and harmaline: opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice.
    Fuller RW, Wong CJ, Hemrick-Luecke SK.
    Life Sci; 1986 Feb 03; 38(5):409-12. PubMed ID: 3945167
    [Abstract] [Full Text] [Related]

  • 15. Monoamine oxidase in pancreatic islets, exocrine pancreas, and liver from rats. Characterization with clorgyline, deprenyl, pargyline, tranylcypromine, and amezinium.
    Lenzen S, Nahrstedt H, Panten U.
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Nov 03; 324(3):190-5. PubMed ID: 6419132
    [Abstract] [Full Text] [Related]

  • 16. E2011 a novel, selective and reversible inhibitor of monoamine oxidase type A.
    Kagaya T, Kajiwara A, Nagato S, Akasaka K, Kubota A.
    J Pharmacol Exp Ther; 1996 Jul 03; 278(1):243-51. PubMed ID: 8764357
    [Abstract] [Full Text] [Related]

  • 17. Comparative effects of dehydropirlindole and other compounds on rat brain monoamine oxidase type A.
    Gerardy J, Dresse A.
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan 03; 26(1):75-9. PubMed ID: 11853123
    [Abstract] [Full Text] [Related]

  • 18. Characteristics of the inhibition of rat brain monoamine oxidase in vitro by MD780515.
    Kan JP, Strolin Benedetti M.
    J Neurochem; 1981 Apr 03; 36(4):1561-71. PubMed ID: 7264651
    [Abstract] [Full Text] [Related]

  • 19. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A.
    Finberg JP.
    Acta Psychiatr Scand Suppl; 1995 Apr 03; 386():8-13. PubMed ID: 7717096
    [Abstract] [Full Text] [Related]

  • 20. The current status of monoamine oxidase and its inhibitors.
    Jarrott B, Vajda FJ.
    Med J Aust; 1987 Jun 15; 146(12):634-8. PubMed ID: 3114597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.